Feedback / Questions
bertilimumab (iCo-008) - iCo Therapeutics, Alexion Pharma
Bertilimumab: Protection of patents until 2021/2022
(Immune Pharma)
-
Oct 10, 2017 -
Corporate Presentation
Patent
•
Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation
http://www.immunepharma.com/wp-content/uploads/2017/10/Immune-Pharma-10-5-17-web.pdf
Oct 10, 2017
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious